Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kitty Nose: Smoking and Nasal Inflammation
NCT03031145Phase 1Withdrawn
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2017
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Change in eosinophils/mL in nasal lavage fluid (NLF). Planned start Apr 2017; status: withdrawn.
Beyond the preview
Go deeper on NCT03031145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031145.